SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.
Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual
Format: Fireside Chat
Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)
Webcast: Click Here
A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
This press release was published by a CLEAR® Verified individual.
| Last Trade: | US$0.97 |
| Daily Change: | 0.09 9.92 |
| Daily Volume: | 172,353 |
| Market Cap: | US$36.940M |
September 16, 2025 September 04, 2025 July 01, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
